Caribou Biosciences, Inc.

NASDAQ:CRBU

Biotechnology

Healthcare
$0.49 -2.74%

-$0.05 today

Market cap
$52.47M
Beta
2.33
P/E (TTM)
-1.1
EPS (TTM)
-$1.39
52W Low $1.20High $3.54

Volume 1.01M

Average 1.83M

CRBU Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Caribou Biosciences, Inc.NASDAQ: CRBU

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit growth accelerates

Q1 FY2026 gross profit of $1.75M rose 186.6% year over year, ahead of the +117.7% change in trailing-twelve-month gross profit. Sequentially, it fell 55.6% from the prior quarter. Over 3 fiscal years it compounded at -9.7% a year.

Context

  • Gross profit amounted to 67.3% of revenue in FY2025, up 6.6 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +186.6% holds above the trailing-twelve-month pace of +117.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.75M-55.6% QoQ
Last fiscal yearDec 2025
$7.51M+23.9% YoY
LTMMar 2026
$9.26M+117.7% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+186.6%——
1 year+23.9%——
3-year CAGR-9.7%——
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
7.51M USD
Year-over-year change
+23.9%
4-year CAGR
-3.4%

Gross Profit vs competitors

How CRBU compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +117.7% is the 3rd highest of 9, against a peer median of +14.7%.
  • Gross profit amounts to 82.6% of revenue for CRBU, versus a peer median of 98.8%.
CRBU Competitors
Gross Profit for CRBU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$68M USD+5.5%-11.0%98.3%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$32.49M USD+1115.8%+118.1%99.3%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$16.33M USD+133.3%—97.7%
PYXSPyxis Oncology, Inc.LTM Mar 2026$13.83M USD——99.8%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$9.26M USD+117.7%-9.7%82.6%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$6.28M USD-73.3%+12.8%22.3%
IVAInventiva S.A.FY2025€1.51M EUR-83.6%-55.4%33.7%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$326K USD+115.4%—144.9%
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$0 USD———
HUMAHumacyte, Inc.LTM Mar 2026-$15.09M USD-917.5%—748.5%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$77.25M USD+23.8%——
Peer median (excluding CRBU) —+14.7%+0.9%98.8%

Competitors are the stored peer set for CRBU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.6M13.85M34.48M9.99M11.16M
Cost of Revenue984K3.64M3.53M3.93M3.65M
Gross Profit8.61M10.21M30.95M6.07M7.51M
Gross Margin89.7%73.7%89.8%60.7%67.3%
Research & Development52.26M82.23M112.08M130.15M109.44M
Selling, General & Admin23.34M38.02M38.46M46.46M37.91M
Operating Expenses75.59M116.61M147.01M172.68M143.71M
Depreciation & Amortization984K3.64M3.53M3.93M3.65M
EBITDA(65.61M)(95.71M)(98.35M)(145.19M)(145.03M)
EBITDA Margin-683.6%-691.0%-285.3%-1452.7%-1299.7%
Operating Income(66.98M)(106.4M)(116.06M)(166.62M)(136.19M)
Operating Margin-697.8%-768.2%-336.6%-1667.2%-1220.5%
Interest Income148K4.6M10.7M08M
Interest Expense8K0000
Other Income / Expenses377K7.05M14.18M17.5M(12.48M)
Income Before Tax(66.6M)(99.35M)(101.88M)(149.11M)(148.68M)
Pre-Tax Margin-693.9%-717.3%-295.5%-1492.0%-1332.3%
Income Tax Expense321K70K193K(9K)(550K)
Net Income(66.92M)(99.42M)(102.07M)(149.11M)(148.13M)
Net Margin-697.3%-717.8%-296.1%-1491.9%-1327.4%
EPS (Basic)(1.11)(1.64)(1.38)(1.65)(1.59)
EPS (Diluted)(1.11)(1.64)(1.38)(1.65)(1.59)
Weighted Avg Shares60.26M60.8M73.81M90.32M93.39M
Weighted Avg Shares (Diluted)60.26M60.8M73.81M90.32M93.39M

Caribou Biosciences, Inc.

NASDAQ:CRBU

Intrinsic Alpha fair value

Locked

Current Price

$0.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.